ClinicalTrials.gg
CompletedNCT04346316Updated Jul 16, 2021

A Phase II Study in Patients With Alopecia Areata

A Phase 2 interventional study of SHR0302 in Alopecia Areata, sponsored by Reistone Biopharma Company Limited. Completed at 34 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2021, 5 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.

Enrollment
18th of 22
94 · median 163
Started
2020
with 1 other
Phase 2
6 of 24
2 open now
Registered
6th of 24
by date
Lead sponsor
2 of 24
Reistone Biopharma Company Limited

Among the 24 studies in Alopecia Areata with a site in China, this one is the 18th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 2, and was the 6th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Alopecia Areata with a site in China, or all of them as a file.
02

Study summary

This is a global Phase 2 study to evaluate the safety and effectiveness of an investigational study drug (called SHR0302) in adults with moderate to severe alopecia areata.

Read the detailed description

The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 3 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18-65 years of age (both inclusive), at the time of ;
  • Must have moderate to severe alopecia areata.

Exclusion criteria

Exclusion Criteria:

  • Other types of alopecia or other diseases that can cause hair loss
  • Other scalp diseases that could interfere with assessment of hair loss/regrowth
  • Any previous use of any Janus kinase (JAK) inhibitor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Active comparator
    SHR0302 Dose#1

    Drug: SHR0302

  • Active comparator
    SHR0302 Dose#2

    Drug: SHR0302

  • Active comparator
    SHR0302 Dose#3

    Drug: SHR0302

  • Placebo comparator
    Placebo

    Drug: SHR0302

Interventions

  • Oral tablets taken once daily (QD)

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in Severity of Alopecia Tool (SALT) score

    Severity of alopecia tool is a quantitative assessment of AA severity based on scalp hair loss

    Time frame: week 24

07

Study locations

34 sites
  • Quest Dermatology Research
    Northridge, California 91324, United States
  • Moore Clinical Research
    Brandon, Florida 33511, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46250, United States
  • Skin Search of Rochester, Inc
    Rochester, New York 14623, United States
  • Dermatologists of Southwest Ohio
    Mason, Ohio 45040, United States
  • The Skin Wellness Center
    Knoxville, Tennessee 37922, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • St George Dermatology and Skin Cancer Centre
    Kogarah, New South Wales 2217, Australia
  • Novatrials
    Kogarah, New South Wales 2289, Australia
  • Veracity Clinical Research
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Sinclair Dermatology
    Melbourne, Victoria 3002, Australia
  • China-Japan Friendship Hospital
    Beijing, Beijing 100029, China
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing 100730, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing, China
  • Peking University People's Hospital
    Beijing, Beijing, China
  • Chongqing Traditional Chinese medicine Hospital
    Chongqing, Chongqing 400011, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400016, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510030, China
  • The Dermatology Hospital of Nanfang Medical University
    Guangzhou, Guangdong, China
  • The Dermatology Hospital of Nanfang Medical University
    Guangzhou, Guangzhou, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • Jiangsu Province People's Hospital
    Nanjin, Jiangsu 210029, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai 200071, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin 300120, China
  • The First Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • SIR RUN RUN Shaw Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jun 2021, 12 months.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Apr 15, 2020
StartActual
May 13, 2020
Primary completionActual
Jun 10, 2021
CompletionActual
Jun 29, 2021
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04346316
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
May 13, 2020
Primary completion
Jun 10, 2021
Completion
Jun 29, 2021
Last update
Jul 16, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion